Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin, Docetaxel, and EBV-CTL for Relapsed/Refractory NPC
NCT00953420Phase 2Completed
- Sponsor
- Baylor College of Medicine
- Start
- Nov 2009
- Primary completion
- Jun 2014
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of autologous Epstein-Barr virus-specific cytotoxic T lymphocytes in nasopharyngeal carcinoma (NPC), sponsored by Baylor College of Medicine. Started Nov 2009; status: completed.
02
Drugs
autologous Epstein-Barr virus-specific cytotoxic T lymphocytes
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT00953420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00953420.